|
|
 |
Dr Linker has developed a new chemotherapy program for adult ALL
which has become the standard of care for this disease. Adding
intensive-dose asparaginase as a fourth agent during induction therapy increased the
complete remission rate to 90%, an improvement that has been confirmed by CALGB.
The addition of ara-C plus podophyllotoxin as part of cyclical consolidation
therapy helped improve overall outcome, with sustained remission in nearly 40%
of patients. He has also explored the use of a new strategy for autologous
transplant for those high-risk patients with ALL who lack suitable allogeneic
donors and who are expected to have a dismal outcome with conventional therapy.
Preliminary results are encouraging, with 40% of patients remaining free of
disease at 5 years. He was among the first American investigators to explore
autologous bone marrow transplantation for AML, exploring the use of more
intensive preparative regimens combined with in-vitro bone marrow purging. Dr.
Linker serves as Director of the UCSF Bone Marrow Transplant Program.
Selected Publications
Moss TJ, Kahn DG, Prilutskaya M, Nugyen N, Benyunes M, Ashby M, Umiel T, Weaver C,
Linker C. Recombinant human thrombopoetin does not enhance
tumor cell mobilization in patients undergoing peripheral blood progenitor cell mobilization. Blood 92 Suppl 1: 722a (1998).
Rini BI, Halabi S, Barrier R, Margolin KA, Avigan D, Logan T, McCarthy PL, Small ES, Linker CA.
CALGB 9003: adoptive immunotherapy by allogeneic stem cell transplantation
for metastatic renal cell carcinoma: An Intergroup phase II study. Blood 104: 231a (2004)
Martin T, Working M, O Malley R, Guglielmo J,, Fischbach N, Damon L, Navarro W, Kaplan L, Jacobs R, Andrews J,
Linker C. Voriconazole is safe and effective as
prophylactic antifungal therapy following allogeneic transplantation. Biology of Blood and Marrow Transplant 11 Suppl 1: 88 (2005).
Information last updated September 2007
|
|
|
